Three unprofitable healthcare companies went public this past week, out of a potential eight IPOs. These included a large biotech targeting rare diseases, a medical device maker, and a synthetic DNA company. The group raised $390 million and averaged a...read more
Orchard Therapeutics, which is developing stem cell gene therapies for rare diseases, raised $200 million by offering 14.3 million shares (up from the 13.3 million previously anticipated) at $14, the low end of the range of $14 to $16. Orchard Therapeutics will...read more
As many as 7 IPOs could raise about $450 million in the week ahead, including 6 healthcare deals. Don't expect all of them to get done. IPOs have sold off alongside the broader markets, while the VIX Volatility Index is in the "IPO postponement zone." read more
Orchard Therapeutics, which is developing stem cell gene therapies for rare diseases, announced terms for its IPO on Tuesday. The London, United Kingdom-based company plans to raise $200 million by offering 13.3 million ADSs at a price range of $14 to $16....read more
US IPO Weekly Recap: 3 healthcare IPOs trade flat
Three unprofitable healthcare companies went public this past week, out of a potential eight IPOs. These included a large biotech targeting rare diseases, a medical device maker, and a synthetic DNA company. The group raised $390 million and averaged a...read more
Gene therapy biotech Orchard Therapeutics prices $200 million IPO at $14, the low end of the range
Orchard Therapeutics, which is developing stem cell gene therapies for rare diseases, raised $200 million by offering 14.3 million shares (up from the 13.3 million previously anticipated) at $14, the low end of the range of $14 to $16. Orchard Therapeutics will...read more
US IPO Week Ahead: Micro-cap healthcare dominates week with up to 7 IPOs
As many as 7 IPOs could raise about $450 million in the week ahead, including 6 healthcare deals. Don't expect all of them to get done. IPOs have sold off alongside the broader markets, while the VIX Volatility Index is in the "IPO postponement zone."read more
Gene therapy biotech Orchard Therapeutics sets terms for $200 million IPO
Orchard Therapeutics, which is developing stem cell gene therapies for rare diseases, announced terms for its IPO on Tuesday. The London, United Kingdom-based company plans to raise $200 million by offering 13.3 million ADSs at a price range of $14 to $16....read more